Study to Assess Functionality, Reliability, and Performance of a Single-Use Auto-Injector With Benralizumab Administered at Home

PHASE3CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

November 10, 2016

Primary Completion Date

August 21, 2017

Study Completion Date

August 21, 2017

Conditions
Asthma
Interventions
BIOLOGICAL

Benralizumab

Benralizumab administered subcutaneously every 4 weeks

Trial Locations (25)

31707

Research Site, Albany

33126

Research Site, Miami

44718

Research Site, Canton

55402

Research Site, Minneapolis

63141

Research Site, St Louis

73034

Research Site, Edmond

75071

Research Site, McKinney

75093

Research Site, Plano

78006

Research Site, Boerne

78229

Research Site, San Antonio

91324

Research Site, Northridge

92506

Research Site, Riverside

92683

Research Site, Westminster

32789-4681

Research Site, Winter Park

T8L 0N2

Research Site, Sherwood Park

L1S 2J5

Research Site, Ajax

L7N 3V2

Research Site, Burlington

K2L 3C8

Research Site, Kanata

L5A 3V4

Research Site, Mississauga

H3G 1L5

Research Site, Montreal

H4J 1C5

Research Site, Montreal

G1G 3Y8

Research Site, Québec

G1V 4W2

Research Site, Québec

J1H 5N4

Research Site, Sherbrooke

G8T 7A1

Research Site, Trois-Rivières

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY